Amphetamine Withdrawal: Symptoms, Timeline & Managing the Crash

Most patients I see come in expecting the crash to feel like a bad flu. What they are not prepared for is waking up on day three unable to feel pleasure in anything, not food, not music, not their children. That anhedonia is the dopamine system running on empty, and it is the single biggest driver of relapse in amphetamine withdrawal. The patients who understand what is happening neurochemically do significantly better than those who just think they are “in a bad mood.”

What Amphetamine Withdrawal Actually Is

Amphetamine withdrawal is the brain’s physiological response to the sudden absence of a drug it has reorganised itself around. Regular amphetamine use floods the synaptic cleft with dopamine, norepinephrine, and serotonin by forcing their release from presynaptic terminals and blocking their reuptake. The brain compensates by downregulating receptor density and reducing its own baseline production of these neurotransmitters. When you stop, the drug is gone but the compensation remains. The result is a deficit state.

This is not a character flaw or weakness. It is receptor adaptation. The DSM-5 classifies amphetamine withdrawal as a distinct clinical syndrome under Stimulant Use Disorder, requiring at least two specific symptoms causing clinically significant distress.

Amphetamine Withdrawal Symptoms: The Full Picture

The Core Crash Symptoms

The term “the crash” is accurate. Dopaminergic tone drops sharply within hours of the last dose. The symptoms that follow reflect that collapse directly.

Fatigue is the most universal symptom. Not tiredness. The kind of exhaustion where getting off the couch feels genuinely impossible. Your brain has been running on artificially elevated catecholamines for weeks or months, and now it has almost none. Sleep follows the same pattern, most people sleep 12 to 18 hours a day in the first few days, and it still does not feel restorative.

Dysphoria and depression come next. The mesolimbic dopamine pathway, which generates motivation and reward signals, is functioning at a fraction of its normal capacity. Food, sex, social contact, nothing registers as rewarding. This is clinical anhedonia, and in severe cases it meets criteria for a major depressive episode.

Cravings during this phase are intense specifically because amphetamines become the only thing the brain predicts will restore normal function. That prediction is neurochemically correct in the short term, which is why it is so hard to override.

Physical Symptoms

The physical symptom burden is real but tends to be less dramatic than opioid or alcohol withdrawal. Increased appetite is almost universal, amphetamines suppress appetite via hypothalamic effects, and that suppression lifts abruptly. Most patients gain 2 to 5 kilograms in the first two weeks.

Headaches are common in the first 48 to 72 hours, driven partly by caffeine co-use changes and partly by cerebral blood flow normalisation. Psychomotor retardation, moving and speaking more slowly than usual, is frequently reported and can be striking in someone who was previously running at high speed. Some patients experience muscle aches and generalised physical discomfort similar to mild flu symptoms.

Psychiatric Symptoms That Warrant Attention

Anxiety and irritability often coexist with depression, particularly in the first 72 hours. The norepinephrine deficit disrupts the locus coeruleus, which regulates arousal and stress response, so the system swings between flat and agitated rather than finding a stable baseline.

Cognitive impairment is significant and often surprises patients. Working memory, processing speed, and executive function are all reduced. This is not permanent, but it can last several weeks in heavy users.

Paranoia and psychotic symptoms that were present during active amphetamine use typically begin to resolve once the drug clears. However, pre-existing amphetamine-induced psychosis can persist and requires separate psychiatric management.

Amphetamine Withdrawal Timeline: What to Expect Day by Day

The timeline above assumes stopping amphetamine use completely. Methamphetamine (including crystal meth and shabu) follows a broadly similar trajectory but with a more pronounced and prolonged crash, reflecting higher potency and more extensive neurotoxic effects on dopaminergic terminals. If you want to understand the differences between these compounds in more detail, the comparison between amphetamine and methamphetamine is worth reading before making assumptions about what your withdrawal will look like.

What Drives Symptom Severity: Risk Factors

Not everyone crashes at the same depth. The severity of amphetamine withdrawal symptoms tracks closely with several factors.

Duration of use matters more than most patients expect. Someone who has used amphetamines daily for three years has a far more adapted dopamine system than someone who binge-used for three months. Longer use means more receptor downregulation, which means a deeper deficit when the drug stops.

Dose is the second factor. Higher daily doses produce greater compensatory adaptation. Patients using prescription-dose amphetamines (10 to 30mg of amphetamine salts) for ADHD generally experience milder withdrawal than someone using 200 to 500mg of illicit amphetamine daily.

Polydrug use significantly complicates the picture. Many amphetamine users co-use benzodiazepines or alcohol to manage stimulant anxiety or to help sleep. When they stop amphetamines, they may simultaneously be in early alcohol or benzodiazepine withdrawal, which carries its own risk profile. Benzodiazepine withdrawal carries serious seizure risk and needs separate clinical assessment. If you have been using both, read about benzodiazepine withdrawal dangers before attempting to stop anything alone.

Pre-existing mental health conditions, particularly depression and anxiety disorders, predict a more difficult crash. The dopamine deficit of withdrawal lands on a system that was already struggling.

Why Amphetamine Withdrawal Cravings Are So Hard to Resist

This deserves its own section because most patients and families underestimate it.

Amphetamine cravings during withdrawal are not purely psychological in the way people mean when they say “it is all in your head.” The nucleus accumbens, which processes reward anticipation, has learned over months or years that amphetamine is the primary source of dopamine signal. In the absence of the drug, that circuit generates craving as a motivational state. It is computationally similar to hunger.

The incentive salience model described by Berridge and Robinson explains this well. Wanting and liking are processed by different neural circuits. During withdrawal, wanting can be high even when the person no longer enjoys the drug and consciously does not want to use. That dissociation is what patients describe as “I know I don’t want to but every part of me is pulling toward it.” Treating this as a willpower failure misses the biology entirely.

Cue-triggered cravings, where a smell, a place, a person, or a time of day triggers intense wanting, can persist for months after the acute crash resolves. This is mediated by glutamatergic plasticity in the prefrontal-to-accumbens pathway. Structured cognitive and behavioural therapy directly targets this circuit.

Managing Amphetamine Withdrawal: What Actually Helps

Medical Management

There is no FDA-approved or TGA-approved pharmacotherapy specifically for amphetamine withdrawal. That does not mean medication is never used. It means it is used for specific symptoms rather than the syndrome as a whole.

Modafinil has the best evidence for reducing amphetamine withdrawal symptoms, particularly fatigue and craving, in the subacute phase. It promotes wakefulness via orexin pathways without the dopaminergic reinforcement of amphetamines. Several randomised controlled trials have shown reduction in craving and improved retention in treatment programs.

Bupropion, which inhibits reuptake of dopamine and norepinephrine, has shown modest benefit for reducing withdrawal severity in some trials. It is sometimes used where co-occurring depression is present.

Mirtazapine has evidence for improving sleep and appetite in the acute crash phase, and one Cochrane-reviewed trial showed it reduced methamphetamine use in regular users.

Antidepressants including SSRIs are often started during withdrawal if there is a co-occurring depressive disorder, though they take two to four weeks to have meaningful effect and do not address the acute crash directly.

Benzodiazepines are sometimes used short-term for acute agitation or anxiety, but require careful monitoring given the abuse potential in this population.

What Supervised Medical Detox Provides That Home Withdrawal Does Not

At Phuket Island Rehab, every admission for stimulant withdrawal starts with a psychiatric and medical assessment. We are specifically looking for pre-existing mood disorders, psychotic symptoms, polysubstance use, and cardiovascular status. Blood pressure, heart rate, and cognitive screening are all part of the initial workup.

The clinical team monitors for the psychiatric complications that home management misses: emerging suicidal ideation, acute psychosis, and the transition from crash-phase depression into a genuine major depressive episode requiring specific treatment.

Sleep is managed actively. The REM rebound and sleep architecture disruption in the first two weeks is one of the most underappreciated drivers of relapse. Patients who are sleeping 4 hours a night and feeling cognitively flat will use almost anything to feel better. Addressing sleep directly reduces that vulnerability.

Psychological Treatment for the Withdrawal Phase

Cognitive behavioural therapy adapted for stimulant withdrawal has the strongest evidence base of any psychological approach. The focus in the early phase is not insight work, it is behavioural activation to counteract psychomotor retardation, craving management through identification of triggers and response interruption, and cognitive restructuring of the nihilistic thinking that characterises anhedonic depression.

Contingency management, where patients receive tangible rewards for negative urine drug screens, has more evidence behind it for stimulant use disorder than for almost any other addiction. It works by providing an external dopamine signal while the internal system recovers.

Amphetamine Withdrawal vs. Other Stimulant Withdrawals

Methamphetamine withdrawal typically produces a more severe and prolonged crash than standard amphetamine withdrawal. If you have been using crystal meth or shabu specifically, the effects of crystal methamphetamine on the dopamine system explain why the recovery trajectory looks different.

Protracted Amphetamine Withdrawal: When Symptoms Last Weeks or Months

A significant minority of heavy amphetamine users experience symptoms well beyond the two to three week acute window. This is sometimes called post-acute withdrawal syndrome (PAWS), though the evidence base for PAWS as a distinct clinical entity is stronger for alcohol and opioids than for stimulants.

What we do see clinically is a prolonged subacute phase, particularly in patients who have used high doses for more than two years. The primary features are anhedonia that persists for weeks to months, difficulty concentrating and processing information, irregular and unrefreshing sleep, and episodic intense cravings triggered by environmental cues.

PET imaging studies of long-term methamphetamine users have documented reduced D2 receptor density in the striatum that persists for months after cessation and only partially recovers over one to two years of abstinence. The good news from the same research: recovery does occur, and it accelerates with structured treatment, good sleep, and sustained abstinence.

The mistake most patients make is interpreting this prolonged phase as evidence that they will never feel normal again. That interpretation drives relapse. What the neuroscience actually shows is that the timeline for dopamine system recovery is longer than most people expect, but the trajectory is consistently positive.

Amphetamine Withdrawal and Mental Health: The Overlap You Need to Know About

Stimulant use disorders have extremely high rates of co-occurring mental health conditions. ADHD, depression, anxiety disorders, PTSD, and bipolar disorder all appear at elevated rates in people presenting for amphetamine withdrawal treatment.

The clinical challenge is that amphetamine withdrawal mimics depression closely enough that distinguishing withdrawal-induced mood disorder from a pre-existing depressive disorder is genuinely difficult in the first two to four weeks. The standard approach is to stabilise the withdrawal, reassess mood at four weeks of abstinence, and then make a diagnostic decision about whether ongoing pharmacotherapy for depression is warranted.

ADHD deserves specific mention. A substantial proportion of people who develop amphetamine use disorder have undiagnosed ADHD and began using stimulants, sometimes prescribed, sometimes not, because the drugs genuinely improved their function. Stopping amphetamines without addressing underlying ADHD significantly increases relapse risk. Proper neuropsychological assessment and, where appropriate, non-stimulant ADHD medication (atomoxetine, bupropion) or carefully monitored stimulant replacement can be part of a complete treatment plan.

The clinical pattern that warrants professional support is not defined by how much you use. It is defined by what happens when you stop or try to cut down. If you experience the symptoms described in this article, significant mood crash, inability to function, cravings that override your own intentions, you are meeting the physiological criteria that the DSM-5 uses to identify Stimulant Use Disorder. That is a medical condition, not a moral failure, and it responds to treatment.

At Phuket Island Rehab, we treat amphetamine and methamphetamine withdrawal in a residential setting on Phuket, Thailand. Our clinical approach combines medical assessment and monitoring in the acute phase with intensive psychological treatment targeting the specific mechanisms that drive stimulant relapse. We work with patients coming from across Southeast Asia and internationally, and we have specific experience with the stimulant use patterns common in this region. Detailed information about our approach is available at our amphetamine addiction treatment page for Thailand.

Amphetamine withdrawal is a predictable neurobiological process driven by the sudden loss of artificially elevated dopamine and norepinephrine signalling. The acute crash peaks between days 2 and 4, dominated by profound fatigue, anhedonia, dysphoria, and cravings. Physical symptoms are present but modest compared to the psychiatric burden. Suicidal ideation in the crash phase is a genuine risk that distinguishes amphetamine withdrawal from the relatively mild physical risk profile it otherwise carries. The subacute phase, lasting two to four weeks, is characterised by gradually improving mood, persistent cognitive fog, and cue-triggered cravings. In heavy, long-term users, reduced dopamine receptor density documented on neuroimaging explains why the recovery timeline extends to months rather than weeks. There is no approved pharmacotherapy that resolves the syndrome, but modafinil, mirtazapine, and bupropion have evidence for specific symptom domains. Cognitive behavioural therapy and contingency management have the strongest evidence base for long-term recovery.

For anyone managing amphetamine withdrawal, the practical priorities are medical assessment to rule out dangerous co-occurring withdrawal from alcohol or benzodiazepines, active psychiatric monitoring through the crash phase, structured sleep support, and the beginning of psychological treatment before the acute phase fully resolves. Home management is possible for mild cases with good social support, but moderate to severe withdrawal, particularly in the presence of depression history, polydrug use, or psychiatric symptoms, belongs in a supervised setting. The most important thing I can tell you is that the anhedonia is not permanent. The dopamine system heals. The timeline is longer than you want it to be, but the direction is always toward recovery.

As John A. Smith of Phuket Island Rehab puts it: “The patients who relapse in amphetamine withdrawal almost always tell me the same thing afterward, they thought the flat, grey feeling was just who they were now. Nobody had told them that the emptiness had a mechanism, and that mechanism was reversible. That is the conversation that changes things.”

How long does amphetamine withdrawal last?

Acute amphetamine withdrawal symptoms typically last one to two weeks, with peak intensity between days 2 and 4. The crash phase resolves for most people within 10 to 14 days, but a subacute phase of low-grade depression, fatigue, and cognitive difficulty can persist for two to four weeks beyond that. In heavy, long-term users, reduced dopamine receptor density means some symptoms, particularly anhedonia and cravings, can continue intermittently for several months. The trajectory is consistently toward improvement with sustained abstinence and structured support.

Can you die from amphetamine withdrawal?

Death from amphetamine withdrawal alone is extremely rare, in contrast to alcohol or benzodiazepine withdrawal where seizures and cardiac events pose direct mortality risk. The serious risk in amphetamine withdrawal is psychiatric: suicidal ideation and suicide attempts during the crash phase, when severe anhedonia and hopelessness combine with impaired decision-making. This is not a hypothetical risk. It is documented clinically and is the primary reason medical supervision during amphetamine withdrawal is recommended rather than optional. Anyone expressing suicidal thoughts during withdrawal should be treated as a medical emergency.

What does the amphetamine crash feel like?

The amphetamine crash feels most commonly like a combination of crushing fatigue, emotional flatness, and an inability to feel pleasure in anything. Most patients describe it as more than tiredness, it is a lack of mental drive and a grey, motivationless state where normal activities feel pointless. Sleep becomes excessive but unrefreshing. Appetite returns forcefully. There is often irritability and anxiety alongside the flat mood, rather than instead of it. Cravings during this phase are intense and feel physical rather than abstract.

What medications help with amphetamine withdrawal symptoms?

No medication is specifically approved for amphetamine withdrawal, but several are used for targeted symptom management. Modafinil has the best trial evidence for reducing fatigue and craving in the subacute phase. Mirtazapine improves sleep and appetite in the acute crash and has shown benefit in reducing methamphetamine use in at least one well-conducted trial. Bupropion addresses dopamine and norepinephrine deficits and may reduce withdrawal severity where co-occurring depression is present. SSRIs are used if a pre-existing depressive disorder is identified, though they do not address the acute crash directly. Medication decisions should be made by a clinician who has assessed the full clinical picture, including polydrug use and psychiatric history.

Is amphetamine withdrawal different from methamphetamine withdrawal?

The underlying mechanism is the same, but methamphetamine withdrawal is generally more severe and lasts longer than standard amphetamine withdrawal. Methamphetamine produces more extensive dopaminergic neurotoxicity, particularly to the terminals of dopamine neurons in the striatum, which means the deficit state is deeper and recovery takes longer. Psychotic symptoms are more common during methamphetamine withdrawal than with amphetamine, and the subacute phase of anhedonia and cognitive impairment is typically more pronounced. Clinically, methamphetamine withdrawal more frequently requires inpatient support.

Should amphetamine withdrawal be managed at home or in a clinic?

Mild amphetamine withdrawal in someone with no psychiatric history, no polydrug use, and reliable social support can be managed at home with medical oversight. Most cases warrant clinical assessment at minimum to rule out concurrent alcohol or benzodiazepine withdrawal, assess suicide risk, and establish a monitoring plan. Inpatient or residential treatment is strongly recommended when there is a history of depression or suicidal ideation, concurrent use of alcohol or benzodiazepines, severe or prolonged heavy use, or prior failed attempts to stop independently. The crash phase is the highest-risk window for relapse, and the quality of support in those first few days has a significant impact on long-term outcomes.

Can you experience amphetamine withdrawal from prescription stimulants like Adderall or Ritalin?

Yes, though typically milder than illicit amphetamine withdrawal when taken at prescribed doses. Prescription amphetamine salts and methylphenidate work through the same dopaminergic and noradrenergic mechanisms, so their discontinuation produces the same qualitative withdrawal syndrome. The severity depends on dose and duration of use. Patients stopping high-dose prescription stimulants used outside of prescribed parameters, or those who have been prescribed therapeutic doses for years, can experience clinically significant withdrawal. If you have ADHD and are stopping stimulant medication, this should be done with your prescribing clinician, since unmanaged ADHD significantly increases the discomfort of withdrawal and the risk of relapse to drug use.